Neuren begins Phase-2 trial for Angelman syndrome drug, shares rise

Neuren Pharmaceuticals

12/07/2022 03:48

** Shares of Neuren Pharmaceuticals  NEU.AX  rise as much as
2% to A$4.030, and extend gains to a second straight session 
    ** Says its Phase-2 clinical trial of drug NNZ-2591 in
Angelman Syndrome, a genetic disorder that causes neurological
and developmental disabilities, is open for enrolment  
 urn:newsml:reuters.com:*:nASX9qMKQY
    ** Says top-line results are anticipated in the first half
of 2023 
    ** NEU is up ~4.8% this year, as of last close

 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))